文章核心观点 - 革命医药公司与顶峰治疗公司达成临床合作，评估革命医药公司的RAS(ON)抑制剂与顶峰治疗公司的ivonescimab联用在多种实体瘤中的安全性和有效性 [1] 合作详情 - 合作评估革命医药公司临床阶段的RAS(ON)抑制剂（多选择性抑制剂daraxonrasib、G12D选择性抑制剂zoldonrasib和G12C选择性抑制剂elironrasib）与顶峰治疗公司的PD - 1 / VEGF双特异性抗体ivonescimab联用的安全性和有效性 [1] - 临床合作旨在评估这些组合在三种优先肿瘤类型（RAS突变非小细胞肺癌、胰腺导管腺癌和结直肠癌）中的效果 [2] - 协议规定顶峰治疗公司提供ivonescimab用于临床研究，革命医药公司为研究主办方，双方保留各自化合物的商业权利，协议为非排他性 [2] 双方表态 - 革命医药公司董事长兼首席执行官表示，daraxonrasib和elironrasib与PD - 1抗体联用有前景，与新型PD - 1双特异性抑制剂联用可能释放更多治疗潜力，期待评估RAS(ON)抑制剂与ivonescimab的组合 [2] - 顶峰治疗公司董事长兼联合首席执行官等表示，很高兴与革命医药公司合作，评估ivonescimab与RAS(ON)抑制剂联用能否改善肺癌和胃肠道癌症患者的预后，认为将ivonescimab与有前景的药物联用很重要 [3] 公司介绍 革命医药公司 - 是一家后期临床肿瘤公司，为RAS成瘾性癌症患者开发新型靶向疗法，研发管线包括RAS(ON)抑制剂，目前daraxonrasib、elironrasib和zoldonrasib处于临床开发阶段，预计RMC - 5127将是下一个进入临床开发的RAS(ON)抑制剂，管线中还有其他RAS(ON)突变选择性抑制剂 [4] 顶峰治疗公司 - 是一家生物制药肿瘤公司，专注于发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法，以改善生活质量、延长寿命和解决未满足的医疗需求 [5] - 成立于2003年，股票在纳斯达克全球市场上市，总部位于佛罗里达州迈阿密，在加利福尼亚州门洛帕克和英国牛津设有办事处 [6] 联系方式 - 革命医药公司媒体与投资者联系方式：media@revmed.com、investors@revmed.com [10] - 顶峰治疗公司媒体与投资者联系方式：首席商务与战略官Dave Gancarz、高级投资者关系总监Nathan LiaBraaten，邮箱investors@smmttx.com、media@smmttx.com [10]

DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018 and uses multi-spectral imaging and artificial intelligence ("AI") algorithms to predict burn healing potential, today announced the submission of its De Novo 510k marketing clearance application to the FDA for the DeepView System, intended for use in burn c ...

Apollo Partners Peter Sinensky and Nancy de Liban said, "Olympus sits at the epicenter of multiple focus areas for Apollo and builds upon our expertise in residential real estate and asset-backed finance origination. This new strategy represents a highly scalable business that is poised to deliver flexible capital solutions to an underbuilt market with favorable long-term macroeconomic tailwinds, and we are pleased to partner with Andrew and leverage his extensive experience and strong track record in the s ...

Dr. Cheng is a practicing cardiac electrophysiologist and engineer. He holds a PhD in Biomedical Engineering from Case Western Reserve University, and has medical training at Mt. Sinai Medical Center, Case Western Reserve University, University of Chicago, and the University of California at San Francisco. He currently holds the position of Clinical Professor of Medicine at Baylor College of Medicine, and President and Medical Director of Texas Heart Rhythm Center, and is Senior Research Scientist and Direc ...

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000 Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equit ...

文章核心观点 澳大利亚知识产权局正式受理Allarity Therapeutics公司针对stenoparib的药物反应预测器（DRP）伴随诊断专利申请，这是公司全球战略关键一步，公司正推进stenoparib临床试验并构建全球知识产权布局 [1][2][3] 专利受理情况 - 澳大利亚知识产权局正式受理公司针对stenoparib的DRP伴随诊断专利申请，涵盖40项权利要求 [1][2] - 授予的专利将于2025年6月26日在《澳大利亚专利官方公报》上正式公布，随后有三个月异议期，如无异议预计20个工作日内授予专利 [2] 公司知识产权布局 - 公司CEO表示此次澳大利亚专利受理是为DRP技术获取国际知识产权保护重要成果，在推进stenoparib二期试验同时正构建全球关键市场知识产权地位 [3] - 公司此前已获得stenoparib DRP欧洲专利，拥有18项药物特异性DRP授予专利，其中8项在美国，美国、加拿大、日本、中国和印度的stenoparib DRP专利申请仍在审理中 [3] Stenoparib介绍 - stenoparib是口服小分子PARP1/2和tankyrase 1/2双重靶向抑制剂，tankyrases作为新兴癌症治疗靶点受关注，因其在调节WNT信号通路中作用，异常WNT/β -连环蛋白信号与多种癌症发展和进展有关，stenoparib有望治疗多种癌症包括卵巢癌 [4] - 公司获得stenoparib全球独家开发和商业化权利，该药最初由卫材株式会社开发，曾用名E7449和2X - 121 [4] 药物反应预测器（DRP）介绍 - 公司用药物特异性DRP筛选可能从特定药物治疗中获益患者，通过治疗前筛选和仅治疗DRP评分足够高患者提高治疗获益率 [5] - DRP方法基于敏感和耐药人类癌细胞系比较，结合细胞系转录组信息、临床肿瘤生物学过滤器和先前临床试验结果，基于患者活检的信使RNA表达谱 [5] - DRP平台在数十项临床研究中能对癌症患者药物治疗临床结果进行统计学显著预测，适用于所有癌症类型，多项抗癌药物相关专利已发表在同行评审文献中 [5] 公司概况 - Allarity Therapeutics是临床阶段生物制药公司，专注开发个性化癌症治疗，重点是用DRP技术为晚期卵巢癌患者开发stenoparib及配套伴随诊断，以筛选最能从stenoparib治疗中获益患者 [6] - 公司总部设在美国，在丹麦有研究设施，致力于满足癌症治疗重大未满足医疗需求 [6]

PRESS RELEASE Amsterdam, June 30, 2025 JDE Peet's (EURONEXT: JDEP), the world's leading pure-play coffee and tea company, today announced that it has repurchased 15,429 shares in the period from June 23, 2025 up to and including June 27, 2025. The shares were repurchased at an average price of EUR 24.10 per share for a total consideration of EUR 0.4 million. These repurchases were made as part of the EUR 250 million share buyback programme announced on March 3, 2025. jde-peets-SBB-periodic-update-june-30-20 ...

About Kratos Defense & Security Solutions Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers' mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading edg ...

文章核心观点 Freshworks宣布其IT和员工服务管理产品中的新AI辅助功能Freshservice Journeys全面可用，该功能可简化跨职能的复杂员工流程，解决企业部门间协调问题，带来诸多好处并获客户认可 [1][2] 产品介绍 - Freshservice Journeys是AI驱动功能，可简化涵盖HR、IT、设施等的复杂工作流程，助力组织在员工过渡期间提供卓越体验 [1] - 该功能可让IT、HR、设施等部门使用无代码工作流程，在入职、离职、晋升和搬迁等关键时刻打造贴心员工体验 [1] 推出背景 - 企业常受遗留系统困扰，部门间缺乏协调和问责导致瓶颈和低效，尤其是在入职等重要员工体验环节 [2] - Freshservice Journeys旨在通过自动化手动任务、改善部门间协调和增强流程可见性解决这些常见挑战 [2] 产品优势 - 客户证明成果显著，如Qualfon的离职流程从数天缩短至数小时，EquiTrust Life Insurance的入职流程更高效，Coherent成功将IT和HR工作流程过渡到Freshservice并计划进一步扩展 [4][6] - 具备AI驱动效率，可处理常规任务，减少团队手动工作并加快任务完成 [5] - 界面易用直观，无代码/低代码界面让管理员轻松配置复杂工作流程，或使用预建模板更快上线 [5] - 实现无缝跨职能协作，分配任务、自动提醒并提供实时进度跟踪，增强协调和问责 [5] - 可灵活适应独特组织需求，使用条件和触发器定制旅程路径 [5] 公司信息 - Freshworks Inc.构建简单服务软件，提供企业级解决方案，超73000家公司信赖其提升服务效率和培养长期忠诚度 [7] - 如需了解Freshservice Journeys更多信息，可访问https://www.freshworks.com/freshservice/journeys [7]

ORLANDO, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. ("Abacus" or the "Company") (NASDAQ: ABL), a leader in the alternative asset management space, today announced that it has commenced an exchange offer (the "Offer") and consent solicitation (the "Consent Solicitation") relating to its (i) outstanding public warrants (the "public warrants") and (ii) outstanding private placement warrants (the "private placement warrants" and, together with the public warrants, the "warrants") to ...